{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:10:04Z","timestamp":1792091404475,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"DOI":"10.7759\/cureus.49306","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T20:48:10Z","timestamp":1700772490000},"source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema"],"prefix":"10.7759","author":[{"given":"Layne","family":"Landry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Witten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie N","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris C","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone C","year":"2017","unstructured":"Stone C, Brown NJ. Angiotensin-converting enzyme inhibitor and other drug-associated angioedema. Immunol Allergy Clin North Am. 2017, 37:483-95.","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.06.019","article-title":"Multinational experience with hypersensitivity drug reactions in Latin America","volume":"113","author":"Jares EJ","year":"2014","unstructured":"Jares EJ, S\u00e1nchez-Borges M, Cardona-Villa R, et al.. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol. 2014, 113:282-9. 10.1016\/j.anai.2014.06.019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2012.04078.x","article-title":"Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria","volume":"42","author":"Cornejo-Garc\u00eda JA","year":"2012","unstructured":"Cornejo-Garc\u00eda JA, Jagemann LR, Blanca-L\u00f3pez N, et al.. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy. 2012, 42:1772-81. 10.1111\/j.1365-2222.2012.04078.x","journal-title":"Clin Exp Allergy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3403","article-title":"The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007","volume":"31","author":"Zilberberg MD","year":"2010","unstructured":"Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010, 31:511-19. 10.2500\/aap.2010.31.3403","journal-title":"Allergy Asthma Proc"},{"key":"ref5","article-title":"The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States","volume":"31","author":"Zilberberg MD","year":"20072010","unstructured":"Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States. Allergy Asthma Proc. 20072010, 31:511-19.","journal-title":"Allergy Asthma Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2019.5.42650","article-title":"Evaluation and management of angioedema in the emergency department","volume":"20","author":"Long BJ","year":"2019","unstructured":"Long BJ, Koyfman A, Gottlieb M. Evaluation and management of angioedema in the emergency department. West J Emerg Med. 2019, 20:587-600. 10.5811\/westjem.2019.5.42650","journal-title":"West J Emerg Med"},{"key":"ref7","article-title":"Angioedema in the emergency department: an evidence-based review","volume":"14","author":"Wilkerson RG","year":"2012","unstructured":"Wilkerson RG. Angioedema in the emergency department: an evidence-based review. Emerg Med Pract. 2012, 14:1-21.","journal-title":"Emerg Med Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-007-0028-9","article-title":"Allergic reactions to nonsteroidal anti-inflammatory drugs: is newer better?","volume":"7","author":"Berges-Gimeno MP","year":"2007","unstructured":"Berges-Gimeno MP, Mart\u00edn-L\u00e1zaro J. Allergic reactions to nonsteroidal anti-inflammatory drugs: is newer better?. Curr Allergy Asthma Rep. 2007, 7:35-40. 10.1007\/s11882-007-0028-9","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/all.12680","article-title":"Angioedema induced by cardiovascular drugs: new players join old friends","volume":"70","author":"Bas M","year":"2015","unstructured":"Bas M, Greve J, Strassen U, Khosravani F, Hoffmann TK, Kojda G. Angioedema induced by cardiovascular drugs: new players join old friends. Allergy. 2015, 70:1196-200. 10.1111\/all.12680","journal-title":"Allergy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Woodard-Grice AV","year":"2010","unstructured":"Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010, 20:532-6. 10.1097\/FPC.0b013e32833d3acb","journal-title":"Pharmacogenet Genomics"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare G","year":"2013","unstructured":"Pare G, Kubo M, Byrd JB, et al.. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013, 23:470-8. 10.1097\/FPC.0b013e328363c137","journal-title":"Pharmacogenet Genomics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160928142814","article-title":"Hypersensitivity reactions to non-steroidal anti-inflammatory drugs","volume":"22","author":"Dona I","year":"2016","unstructured":"Dona I, Salas M, Perkins JR, et al.. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Pharm Des. 2016, 22:6784-802. 10.2174\/1381612822666160928142814","journal-title":"Curr Pharm Des"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown NJ","year":"1996","unstructured":"Brown NJ, Ray WA, Snowden M, et al.. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996, 60:8-13. 10.1016\/S0009-9236(96)90161-7","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","author":"Mahmoudpour SH","year":"2016","unstructured":"Mahmoudpour SH, Baranova EV, Souverein PC, Asselbergs FW, de Boer A, Maitland-van der Zee AH. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2016, 82:1647-59. 10.1111\/bcp.13090","journal-title":"Br J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis JB","year":"2005","unstructured":"Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, Levy E. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005, 165:1637-42. 10.1001\/archinte.165.14.1637","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.05.003","article-title":"Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema","volume":"1","author":"Straka B","year":"2013","unstructured":"Straka B, Nian H, Sloan C, et al.. Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol Pract. 2013, 1:468-73.e1-4. 10.1016\/j.jaip.2013.05.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0803977","article-title":"Clinical practice. Hereditary angioedema","volume":"359","author":"Zuraw BL","year":"2008","unstructured":"Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008, 359:1027-36. 10.1056\/NEJMcp0803977","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)09137-X","article-title":"Plasma bradykinin in angio-oedema","volume":"6","author":"Nussberger J","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, et al.. Plasma bradykinin in angio-oedema. Lancet Lond Engl. 1998, 6:1693-7. 10.1016\/S0140-6736(97)09137-X","journal-title":"Lancet Lond Engl"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork K","year":"2006","unstructured":"Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006, 119:267-74. 10.1016\/j.amjmed.2005.09.064","journal-title":"Am J Med"},{"key":"ref20","article-title":"Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico (Article in Spanish)","volume":"51","author":"V\u00e1zquez Nava F","year":"2004","unstructured":"V\u00e1zquez Nava F, Almeida Arvizu VM, S\u00e1nchez Nuncio HR, Villanueva Carreto Mde L, Guidos Fogelbach GA. Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico (Article in Spanish). Rev Alerg Mex. 2004, 51:181-8.","journal-title":"Rev Alerg Mex"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/lary.22349","article-title":"Management of angiotensin-converting enzyme inhibitor-induced angioedema","volume":"121","author":"Al-Khudari S","year":"2011","unstructured":"Al-Khudari S, Loochtan MJ, Peterson E, Yaremchuk KL. Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2011, 121:2327-34. 10.1002\/lary.22349","journal-title":"Laryngoscope"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2005.00352.x","article-title":"Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?","volume":"59","author":"Longhurst HJ","year":"2005","unstructured":"Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?. Int J Clin Pract. 2005, 59:594-9. 10.1111\/j.1742-1241.2005.00352.x","journal-title":"Int J Clin Pract"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.05.037","article-title":"Novel therapies for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review of current evidence","volume":"53","author":"Riha HM","year":"2017","unstructured":"Riha HM, Summers BB, Rivera JV, Van Berkel MA. Novel therapies for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review of current evidence. J Emerg Med. 2017, 53:662-79. 10.1016\/j.jemermed.2017.05.037","journal-title":"J Emerg Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(69)91295-1","article-title":"Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma","volume":"15","author":"Pickering RJ","year":"1969","unstructured":"Pickering RJ, Good RA, Kelly JR, et al.. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet Lond Engl. 1969, 15:326-30. 10.1016\/s0140-6736(69)91295-1","journal-title":"Lancet Lond Engl"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2004.09.015","article-title":"Fresh frozen plasma for acute exacerbations of hereditary angioedema","volume":"22","author":"Hill BJ","year":"2004","unstructured":"Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema. Am J Emerg Med. 2004, 22:633. 10.1016\/j.ajem.2004.09.015","journal-title":"Am J Emerg Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2007.02.024","article-title":"Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department","volume":"33","author":"Pekdemir M","year":"2007","unstructured":"Pekdemir M, Ersel M, Aksay E, Yanturali S, Akturk A, Kiyan S. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med. 2007, 33:137-9. 10.1016\/j.jemermed.2007.02.024","journal-title":"J Emerg Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12019","article-title":"Non-histaminergic angioedema: focus on bradykinin-mediated angioedema","volume":"43","author":"Busse PJ","year":"2013","unstructured":"Busse PJ, Buckland MS. Non-histaminergic angioedema: focus on bradykinin-mediated angioedema. Clin Exp Allergy. 2013, 43:385-94. 10.1111\/cea.12019","journal-title":"Clin Exp Allergy"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji A","year":"2008","unstructured":"Banerji A, Clark S, Blanda M, et al.. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2008, 100:327-32. 10.1016\/S1081-1206(10)60594-7","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/0194599815588909","article-title":"Predictors of airway intervention in angiotensin-converting enzyme inhibitor-induced angioedema","volume":"153","author":"Kieu MC","year":"2015","unstructured":"Kieu MC, Bangiyev JN, Thottam PJ, Levy PD. Predictors of airway intervention in angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg. 2015, 153:544-50. 10.1177\/0194599815588909","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/039463200301600103","article-title":"Immediate allergic reactions to beta-lactams: diagnosis and therapy","volume":"16","author":"Romano A","year":"2003","unstructured":"Romano A, Mondino C, Viola M, Montuschi P. Immediate allergic reactions to beta-lactams: diagnosis and therapy. Int J Immunopathol Pharmacol. 2003, 16:19-23. 10.1177\/039463200301600103","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref31","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata N","year":"2012","unstructured":"Inomata N. Recent advances in drug-induced angioedema. Allergol Int Off J Jpn Soc Allergol. 2012, 61:545-57.","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00678.x","article-title":"Diagnosis of nonimmediate reactions to beta-lactam antibiotics","volume":"59","author":"Romano A","year":"2004","unstructured":"Romano A, Blanca M, Torres MJ, et al.. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004, 59:1153-60. 10.1111\/j.1398-9995.2004.00678.x","journal-title":"Allergy"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection","volume":"13","author":"Long AN","year":"2011","unstructured":"Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011, 13:244-51. 10.1111\/j.1751-7176.2011.00434.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref34","article-title":"Hypertension in Diabetes","author":"Naha S","year":"2000","unstructured":"Naha S, Gardner MJ, Khangura D, et al.. Hypertension in Diabetes. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (ed): South Dartmouth (MA), MDText.com, Inc; 2000."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000298","article-title":"Epidemiology of comorbidities in patients with hypertension","volume":"31","author":"Shrestha PL","year":"2016","unstructured":"Shrestha PL, Shrestha PA, Vivo RP. Epidemiology of comorbidities in patients with hypertension. Curr Opin Cardiol. 2016, 31:376-80. 10.1097\/HCO.0000000000000298","journal-title":"Curr Opin Cardiol"},{"key":"ref36","article-title":"Dipeptidyl Peptidase IV [DPP IV] Inhibitors","author":"Kasina SVSK","unstructured":"Kasina SVSK, Baradhi KM. Dipeptidyl Peptidase IV [DPP IV] Inhibitors. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing;"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown NJ","year":"2009","unstructured":"Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009, 54:516-23. 10.1161\/HYPERTENSIONAHA.109.134197","journal-title":"Hypertension"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.02.012","article-title":"DPP-4 inhibitors and angioedema: a cause for concern?","volume":"106","author":"Byrd JS","year":"2011","unstructured":"Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern?. Ann Allergy Asthma Immunol. 2011, 106:436-8. 10.1016\/j.anai.2011.02.012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref39","unstructured":"Onglyza (saxagliptin). Prescribing information. (2015). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022350s016lbl.pdf."},{"key":"ref40","unstructured":"Januvia (sitagliptin). Prescribing information. (2023). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021995s019lbl.pdf."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica BM","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al.. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369:1317-26. 10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.03.015","article-title":"Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database","volume":"8","author":"Lepelley M","year":"2020","unstructured":"Lepelley M, Khouri C, Lacroix C, Bouillet L. Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database. J Allergy Clin Immunol Pract. 2020, 8:2406-2408.e1. 10.1016\/j.jaip.2020.03.015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17366-x","article-title":"Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)","volume":"12","author":"Ohyama K","year":"2022","unstructured":"Ohyama K, Shindo J, Takahashi T, Takeuchi H, Hori Y. Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS). Sci Rep. 2022, 12:13122. 10.1038\/s41598-022-17366-x","journal-title":"Sci Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00257","article-title":"Neprilysin inhibitors and bradykinin","volume":"5","author":"Campbell DJ","year":"2018","unstructured":"Campbell DJ. Neprilysin inhibitors and bradykinin. Front Med (Lausanne). 2018, 5:257. 10.3389\/fmed.2018.00257","journal-title":"Front Med (Lausanne)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D'Elia E","year":"2017","unstructured":"D'Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017, 19:710-17. 10.1002\/ejhf.799","journal-title":"Eur J Heart Fail"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto K","year":"2021","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021, 44:1239-50. 10.1038\/s41440-021-00706-1","journal-title":"Hypertens Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis JB","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004, 17:103-11. 10.1016\/j.amjhyper.2003.09.014","journal-title":"Am J Hypertens"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers SA","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016, 133:1115-24. 10.1161\/CIRCULATIONAHA.115.018622","journal-title":"Circulation"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000017284.77838.87","article-title":"Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach","volume":"33","author":"Molinaro G","year":"2002","unstructured":"Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke. 2002, 33:1712-16. 10.1161\/01.str.0000017284.77838.87","journal-title":"Stroke"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308097","article-title":"Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke","volume":"86","author":"Hurford R","year":"2015","unstructured":"Hurford R, Rezvani S, Kreimei M, et al.. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatry. 2015, 86:520-3. 10.1136\/jnnp-2014-308097","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600096","article-title":"Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice","volume":"25","author":"Gr\u00f6ger M","year":"2005","unstructured":"Gr\u00f6ger M, Lebesgue D, Pruneau D, Relton J, Kim SW, Nussberger J, Plesnila N. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2005, 25:978-89. 10.1038\/sj.jcbfm.9600096","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0859-x","article-title":"ACE inhibitor-induced angioedema: a review","volume":"20","author":"Kostis WJ","year":"2018","unstructured":"Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018, 20:55. 10.1007\/s11906-018-0859-x","journal-title":"Curr Hypertens Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/207564-angiotensin-converting-enzyme-inhibitors-and-other-medications-associated-with-angioedema","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:21Z","timestamp":1707509421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/207564-angiotensin-converting-enzyme-inhibitors-and-other-medications-associated-with-angioedema"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.49306","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}